Literature DB >> 12120413

Potential cardioprotective actions of no-releasing aspirin.

John L Wallace1, Louis J Ignarro, Stefano Fiorucci.   

Abstract

The use of low doses of aspirin on a daily basis has increased greatly in the past 20 years, based on observations that it can significantly reduce the risk of heart attacks and strokes. However, aspirin can also cause severe damage to the stomach. A modified version of aspirin that releases nitric oxide has been developed that seems to offer important advantages over its 103-year-old parent--namely, improved protection for the heart without the unwanted effects on the stomach.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12120413     DOI： 10.1038/nrd794

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  32 in total

1.  Intracellular release of nitric oxide by NCX 972, an NO-releasing metronidazole, enhances in vitro killing of Entamoeba histolytica.

Authors:  Anna Sannella; Luigi Gradoni; Tiziana Persichini; Ennio Ongini; Giorgio Venturini; Marco Colasanti
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Sildenafil offers protection against NSAID-induced gastric injury.

Authors:  Deborah A Sawatzky; Ian L Megson; Adriano G Rossi
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 3.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 4.  Building a better aspirin: gaseous solutions to a century-old problem.

Authors:  J L Wallace
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

Review 5.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

6.  Influence of hydrocortisone, prednisolone, and NO association on the evolution of acute pancreatitis.

Authors:  Laura Iris Cosen-Binker; Marcelo Gustavo Binker; Rodica Cosen; Gustavo Negri; Osvaldo Tiscornia
Journal:  Dig Dis Sci       Date:  2006-05-03       Impact factor: 3.199

7.  NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Carlos A Velázquez-Martínez; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2015-09-21       Impact factor: 5.858

Review 8.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

9.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

10.  Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.

Authors:  Claudio Napoli; Eric Ackah; Filomena De Nigris; Piero Del Soldato; Francesco P D'Armiento; Ettore Crimi; Mario Condorelli; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.